Product Description
Asenapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Asenapine is used alone or in combination with other medications to treat or prevent episodes of mania (frenzied, abnormally excited mood) or mixed mania (frenzied, abnormally excited mood and symptoms of depression) in adults and children 10 years of age and older with bipolar I disorder (manic depressive disorder; a disease that causes episodes of mania, episodes of depression and other abnormal moods). Asenapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a610015.html)
Mechanisms of Action: 5-HT2A Antagonist,D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Sublingual
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/26/2023 |
News Article |
Saphris (Asenapine) Market Upcoming Outlook 2023-2030 |
|
09/18/2023 |
News Article |
Asenapine Market Overall Study Report With Top Players and Their Future Strategies, 2023-2031 |
|
09/09/2023 |
News Article |
The Mood Stabilizers market is projected to experience growth over the forecast period of 2023 to 2030, driven by new trend analysis and competition tracking, with a CAGR of 6.4%. |
|
08/02/2023 |
News Article |
Global Transdermal CNS Therapeutics Market Research 2023 |